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Hemopure ® , an ultrapurified polymerized hemoglobinbased oxygen-carrying solution, is currently undergoing evaluation in elective surgery patients [1] . This experimental drug may obscure routine clinical chemistry assays because it is naturally pigmented and circulates in the plasma [2] . Because chemistry analyzers use colorimetric methods for many of their tests, the presence of Hemopure in a sample may cause interference in the assay, depending upon the instrument used, the methodology, and the reagents. To obtain accurate chemistry results for both the clinical study and for patient management, it was necessary to determine the extent of these interferences. At each clinical trial site, the chemistry analyzers were challenged with samples containing Hemopure up to 50 g/L to determine the maximum amount of Hemopure that may be present in a sample to obtain accurate results for each test. Hitachi (Boehringer Mannheim Diagnostics) and Ektachem/Vitros (Johnson & Johnson Clinical Diagnostics) chemistry analyzers were the most widely used instruments among the clinical trial sites investigated.
Twenty-two chemistry tests were evaluated with Hemopure on Ektachem/Vitros (models 700 and 950) and Hitachi (models 717, 747, and 911) analyzers with manufacturer-specified reagents and methodologies. Samples were prepared by using the method described in the interference testing guidelines from the NCCLS [3] . A single serum pool was split into two volumes. One volume was diluted with Hemopure while the other was diluted equivalently with water. The two volumes were then combined to obtain 26 samples containing increasing concentrations of Hemopure ranging from 0 to 50 g/L, while maintaining constant analyte concentration. This Hemopure range was chosen since it would encompass the whole spectrum of concentrations observed in vivo throughout the course of the clinical trials being conducted at the time. These interference samples were analyzed in nine hospitals participating in the Hemopure clinical trials. All instruments that would be used to test samples from patients in the clinical trial were challenged, and most sites possessed more than one model of Hitachi or Ektachem, often with a combination of the two types of analyzers. Results obtained from each instrument and each analyte were compared against the theoretical value, and the percent differences were calculated. As a starting point, an analyte was considered free from interference if percent differences did not exceed 5% for electrolytes, 20% for enzymes, and 10% for all other analytes. The laboratory director of each institution adjusted these ranges according to his/her own laboratory's criteria based both on statistical and clinical significance. Each director determined the maximum amount of Hemopure that could be present in a sample and still obtain a valid result [4, 5] .
The average magnitude of change for all analytes at three concentrations of Hemopure is reported in Table 1 for both the Hitachi 747 and the Ektachem/Vitros 700. The maximum amount of Hemopure allowable in a specimen to obtain an interference-free result for the individual assays on each Ektachem/Vitros and Hitachi instrument was averaged and also reported in Table 1 . Sodium, potassium, and chloride assays on all instruments were not affected by the presence of Hemopure in a specimen since all three tests use ion-selective electrode methodology, which is not color dependent. The other tests that showed little to no interference by Hemopure for concentrations up to 50 g/L were aspartate aminotransferase (AST), calcium, urea nitrogen, creatine kinase, and glucose. Both the Ektachem and Hitachi analyzers could not accurately measure albumin, bilirubin, alkaline phosphatase, and lactate dehydrogenase in the presence of Hemopure. The remaining analytes showed various degrees of interference, with the Ektachem analyzers performing better with creatinine, lipase, magnesium, and uric acid, whereas Hitachi analyzers had more success in analyzing alanine aminotransferase (ALT), amylase (model 911), and total protein.
Hospital laboratories have been confident in reporting results in clinical trials using the data obtained through these interference studies. However, as hemoglobin-based blood substitutes come closer to FDA approval, it has become apparent that the manufacturers of chemistry analyzers would benefit from working with the blood substitute companies to find a way to overcome the interferences in their assays. 
